

# INTRODUCING A PURE PLAY LIFE SCIENCES & DIAGNOSTICS COMPANY

## Transaction Features

- Announces agreement with intention to divest the **Analytical, Food, and Enterprise Services businesses** to **New Mountain Capital** for a **total consideration of \$2.45 billion**, including \$2.3 billion in cash and **\$150 million of future contingent consideration**
- The PerkinElmer Life Sciences and Diagnostic business will adopt a **new name and brand** – details to be announced prior to closing
- Stock will continue to trade as PerkinElmer (PKI) until **ticker symbol change is made effective at closing**
- Expected to close in **1Q 2023**

“We will be a **pure-play, high-growth, high-margin Life Sciences & Diagnostics** company with unique scale. The Company’s increased financial strength will support **accelerated investment into attractive end markets** across science and disease, and drive **advanced research, discovery, and improve global health.**”



**Prahlad Singh**  
President and Chief Executive Officer, PerkinElmer Inc.

## Strategic Rationale

**Creates a Faster Growing, Higher Margin Company with Scale**

**Increases Focus on Life Sciences and Diagnostics**

**Accelerates Innovation and Capital Deployment**

## Who We Are

### LIFE SCIENCES


- ✓ Top-tier **pre-clinical research & discovery franchise**
- ✓ Attractive and expanded positions in **biologics and cell & gene therapy**
- ✓ Complete workflow coverage seamlessly integrated with **automation & informatics**

**\$20B+ TAM**

### DIAGNOSTICS

- ✓ Leading solutions in **infectious disease & autoimmune markets**
- ✓ Continued leadership in **reproductive health workflows**
- ✓ Enhanced **'omics sample prep** market position

**\$35B+ TAM**



**~11,000**

**Total Employees**

**~80%**

**Recurring Revenue**

**10%+**

**Expected Organic Growth**